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Abstract
Background: Hereditary hemorrhagic telangiectasia (HHT) is caused by muta-
tions in TGFb/BMP9 pathway genes and characterized by vascular malformations
(VM) including arteriovenous malformations (AVM) in lung, liver, and brain,
which lead to severe complications including intracranial hemorrhage (ICH) from
brain VM. The clinical heterogeneity of HHT suggests a role for genetic modifier
effects. Common variants in loci that modify phenotype severity in Tgfb knockout
mice were previously reported as associated with lung AVM in HHT. Common
variants in candidate genes were reported as associated with sporadic brain AVM
and/or ICH. We investigated whether these variants are associated with HHT
organ VM or with ICH from brain VM in 752 Caucasian HHT patients enrolled
by the Brian Vascular Malformation Consortium.
Methods: We genotyped 11 candidate variants: four variants reported as associated
with lung AVM in HHT (PTPN14 rs2936018, USH2A rs700024, ADAM17
rs12474540, rs10495565), and seven variants reported as associated with sporadic
BAVM or ICH (APOE e2, ANGPTL4 rs11672433, EPHB4 rs314308, IL6 rs1800795,
IL1B rs1143627, ITGB8 rs10486391, TNFA rs361525). Association of genotype with
any VM, lung AVM, liver VM, brain VM or brain VM ICH was evaluated by multi-
variate logistic regression adjusted for age, gender, and family clustering.
Results: None of the 11 variants was significantly associated with any phenotype.
There was a trend toward association of USH2A rs700024 with ICH (OR = 2.77,
95% CI = 1.13–6.80, p = .026).
Conclusion: We did not replicate previously reported associations with HHT lung
AVM and variants in Tgfb modifier loci. We also did not find significant associations
between variants reported in sporadic brain AVM and VM or ICH in HHT.
KEYWORD S
arteriovenous malformation, genetic modifiers, hereditary hemorrhagic telangiectasia, intracerebral
hemorrhage, vascular malformation
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1 | INTRODUCTION
Hereditary hemorrhagic telangiectasia (HHT) is caused by
mutations in TGFb/BMP9 pathway genes, most commonly
ENG (OMIM 131195) or ACVRL1 (ALK1, OMIM
601284). HHT is characterized by vascular malformations
(VM) ranging from small skin and mucosal telangiectases
to arteriovenous malformations (AVM) in lung, liver, and
brain, which can lead to severe complications including
intracranial hemorrhage (ICH) from ruptured brain VM.
The clinical heterogeneity of HHT suggests a potential role
for genetic modifier effects. Identification and validation of
such modifiers could inform disease prognosis and guide
clinical management of HHT patients and provide poten-
tially useful stratifier biomarkers for clinical trials. A few
such genetic associations with HHT disease features have
been reported. Common variants in two loci that modify
phenotype severity in Tgfb knockout mice (TGFb modifier
loci) have been associated with lung AVM in HHT fami-
lies (Benzinou et al., 2012; Kawasaki et al., 2014). We
previously showed that the ACVRL1 c.314-35A>G poly-
morphism, associated with sporadic brain AVM (Paw-
likowska et al., 2005; Simon et al., 2006), is also
associated with VM in HHT, but only among patients with
ENG mutations (Pawlikowska et al., 2015). Common vari-
ants in other candidate genes have previously been
reported to be associated with sporadic BAVM (Kim et al.,
2009; Mikhak et al., 2011; Pawlikowska et al., 2005; Su
et al., 2010) or with sporadic BAVM ICH (Achrol et al.,
2006, 2007; Hysi et al., 2007; Pawlikowska et al., 2004,
2006; Weinsheimer et al., 2009). We investigated whether
the four TGFb modifier locus variants previously reported
in HHT lung AVM and seven variants from sporadic
AVM studies are associated with organ VM and with brain
VM ICH in a large cohort of Caucasian HHT patients
enrolled by the Brain Vascular Malformation Consortium
(BVMC) (Akers et al., 2013).
2 | MATERIALS AND METHODS
2.1 | Ethical compliance
The study protocol was approved by the institutional
review board at each recruiting center. All patients pro-
vided written informed consent for genetic studies and a
blood or saliva sample for DNA extraction.
2.2 | Cohort
The study includes 752 Caucasian HHT patients enrolled
by the BVMC at multiple recruiting centers in the US,
Canada, and the Netherlands between 2010 and 2015.
Cohort recruitment has been previously described (Akers
et al., 2013; Pawlikowska et al., 2015). Patients were
screened for organ VM and other clinical features accord-
ing to standard clinical practice and International HHT
Guidelines (Faughnan et al., 2011), including: comprehen-
sive history, physical, routine blood tests, and clinical
screening for recurrent spontaneous epistaxis and HHT-
related gastrointestinal bleeding. All patients were screened
for pulmonary AVM by contrast echocardiography or by
chest CT. All patients were screened for brain VM by mag-
netic resonance imaging. If screening was positive for pul-
monary AVM or brain VM (Krings et al., 2015), patients
underwent further diagnostic imaging and treatment, where
appropriate. For liver VM, all patients underwent clinical
screening (chronic right upper quadrant pain, portal hyper-
tension, high-output heart failure, liver bruit on examina-
tion, abnormal liver function tests) as well as
echocardiography for high-output cardiopathy. If screening
was positive, then diagnostic liver imaging was performed
(ultrasound Doppler, contrast CT or contrast MRI) and
therapy recommended where appropriate. The BVMC HHT
cohort targets 25% brain VM-positive patients; other char-
acteristics are similar to other cohorts (Letteboer et al.,
2006; Nishida et al., 2012). Brain VM ICH included any
ICH during HHT disease course (prior to enrollment or
during follow-up, including after brain VM treatment). For
lung AVM, we also defined a severe subphenotype as: dif-
fuse lung AVM and/or feeding artery diameter of largest
lung AVM ≥5 mm and/or presence of any of the following
complications: ischemic stroke, brain abscess, massive
hemoptysis, spontaneous hemothorax.
2.3 | Genotyping
DNA was extracted at the NINDS Repository at Coriell
Institute (http://ccr.coriell.org/Sections/Collections/NINDS),
or at UCSF (saliva). We genotyped 11 candidate variants
including seven variants from sporadic BAVM studies
(APOE e2 haplotype comprising rs7412 and rs429358
(Achrol et al., 2007; Pawlikowska et al., 2006), ANGPTL4
rs11672433 (Mikhak et al., 2011), EPHB4 rs314308
(Weinsheimer et al., 2009), IL6-174G>C rs1800795 (Kim
et al., 2008; Pawlikowska et al., 2004), IL1B-31T>C
rs1143627 (Kim et al., 2009), ITGB8 rs10486391 (Su
et al., 2010), TNFA-238G>A rs361525 (Achrol et al.,
2006, 2007)), and four variants in TGFb modifier loci
(PTPN14 rs2936018, USH2A rs700024 (Benzinou et al.,
2012), ADAM17 rs12474540 and rs10495565 (Kawasaki
et al., 2014)) using commercially available Taqman assays
according to manufacturer’s instructions (Applied Biosys-
tems, Foster City, CA). Genotypes were scored by investi-
gators blinded to phenotype. All genotype call rates were
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>95%. All variants were consistent with Hardy–Weinberg
equilibrium (p > .05).
2.4 | Statistical analysis
Genotypes were collapsed for analysis into risk genotype
carriers versus noncarriers according to published associa-
tions with sporadic BAVM (Achrol et al., 2006, 2007;
Hysi et al., 2007; Kim et al., 2009; Mikhak et al., 2011;
Pawlikowska et al., 2004, 2005, 2006; Su et al., 2010;
Weinsheimer et al., 2009). For the four TGFb modifier
variants, the published analysis (Benzinou et al., 2012;
Kawasaki et al., 2014) was for familial transmission, which
we cannot perform in our nonfamilial cohort, so we used
an additive model for the minor (risk) allele, as this is the
most general genetic model for a case–control analysis with
the fewest additional assumptions. Association of genotype
with presence of Any VM (pulmonary, liver or brain), pul-
monary AVM, liver VM, brain VM, and ICH from brain
VM was evaluated by multivariable logistic regression
adjusted for age at last follow-up, gender and family clus-
tering. The same direction of effect (risk genotype) as pre-
viously published was required. The statistical significance
threshold was adjusted for 11 variants tested and set at
p = .0045. We also performed secondary analyses stratified
by HHT mutation (ENG or ACVRL1) for all phenotypes
except ICH (where the N of BAVM patients with known
HHT mutations was too small to accommodate multivariate
analyses for nine variants), and of the severe lung AVM
phenotype (to evaluate the effect of a more stringent phe-
notype definition). One variant-phenotype analysis could
not be evaluated with multivariable logistic regression due
to perfect prediction; we instead provide results from uni-
variable exact logistic regression.
3 | RESULTS
Table 1 shows demographic and clinical characteristics of
the study cohort. Among 752 Caucasian HHT patients,
52% had pulmonary AVM, 20% had liver VM and 21%
had brain VM. 20% (30/153) of brain VM cases had ICH
(prior to enrollment or during follow-up).
None of the 11 variants was significantly associated
with VM in any organ or with ICH (Table 2). We did not
replicate the previously reported associations of four TGFB
modifier variants (Benzinou et al., 2012; Kawasaki et al.,
2014) with HHT lung AVM. There was a trend toward
association of one of these variants, USH2A rs700024, with
ICH from brain VM (OR = 2.77, 95% CI = 1.13–6.80,
p = .026).
In secondary analysis, we detected no statistically sig-
nificant associations between the severe lung AVM subphe-
notype (100 out of 664 patients (15%) with data available)
and the four TGFB modifier loci SNPs (ORs between 0.87
and 0.99, all p > .33). In analysis stratified by ENG or
ACVRL1 HHT mutation, among ENG mutation carriers
only, liver VM were associated with ADAM17 rs12474540
(OR = 2.82, 95% CI = 1.37–4.30, p = .002, Table S1).
There was also a trend toward association of liver VM with
ADAM17 rs10495565 (OR = 2.28, 95% CI = 1.23–4.20,
p = .009), and with PTPN14 rs2936018 (OR = 2.82, 95%
CI = 1.31–6.08), p = .008) (Table S1).
4 | DISCUSSION
We did not replicate the previously reported associations
between four TGFB modifier loci variants with HHT lung
AVM (Benzinou et al., 2012; Kawasaki et al., 2014) in the
TABLE 1 Demographic characteristics and HHT phenotypes of study cohort
Characteristic All Subjects ENG mutation ACVRL1 mutation p
Female sex 437/752 (58%) 143/240 (60%) 109/200 (55%) .289
Age at last follow-up (year) 47.4  19.6 46.1  19.0 49.0  20.2 .121
HHT mutation: n/a
ENG 240/455 (53%) 240/240 (100%) n/a
ACVRL1 200/455 (44%) n/a 200/200 (100%)
SMAD4 15/455 (3%) n/a n/a
Any VM 526/728 (72%) 202/238 (85%) 101/194 (52%) <.001
Lung AVM 378/730 (52%) 170/235 (72%) 37/195 (19%) <.001
Liver VM 144/717 (20%) 24/230 (10%) 56/196 (29%) <.001
Brain VM 156/752 (21%) 78/240 (33%) 22/200 (11%) <.001
ICH from brain VM 30/153 (20%) 14/78 (18%) 5/22 (23%) .759
Values are no. observed with the specified characteristic over the total no. of nonmissing observations or mean  standard deviation.
p, comparison of ACVRL1 and ENG subjects using Fisher’s exact test or a two-sample t-test.
AVM, arteriovenous malformation; ICH, intracerebral hemorrhage; VM, vascular malformation.
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TABLE 2 Association of candidate variant genotype with HHT phenotypes
Phenotype Polymorphism (risk genotypes) n OR 95% CI p
Any VM APOE e2 713 0.83 0.52-1.34 .452
ANGPTL4 rs11672433 (AA or AG) 708 0.99 0.66-1.49 .977
EPHB4 rs314308 (AA or AG) 719 0.76 0.53-1.08 .124
IL1B-31T>C, rs1143627 CC) 723 0.73 0.44-1.21 .222
IL6-174G>C rs1800795 (GG) 714 0.87 0.61-1.24 .443
ITGB8 rs10486391 (AA) 725 0.83 0.58-1.19 .311
TNF-238G>A rs361525 (AA or AG) 722 0.56 0.32-1.00 .048
ADAM17 rs10495565 726 1.04 0.81-1.33 .775
ADAM17 rs12474540 724 1.01 0.80-1.28 .942
PTPN14 rs2936018 717 0.96 0.71-1.29 .784
USH2A rs700024 708 1.12 0.72-1.76 .613
Brain VM APOE e2 737 0.84 0.50-1.40 .494
ANGPTL4 rs11672433 (AA or AG) 732 0.78 0.50-1.20 .256
EPHB4 rs314308 (AA or AG) 743 1.28 0.89-1.84 .181
IL1B-31T>C, rs1143627 CC) 746 1.00 0.57-1.78 .988
IL6-174G>C rs1800795 (GG) 738 0.54 0.36-0.83 .005
ITGB8 rs10486391 (AA) 749 0.92 0.63-1.37 .696
TNF-238G>A rs361525 (AA or AG) 746 1.01 0.59-1.74 .959
ADAM17 rs10495565 750 0.85 0.65-1.10 .213
ADAM17 rs12474540 748 0.79 0.61-1.03 .085
PTPN14 rs2936018 741 1.05 0.77-1.44 .749
USH2A rs700024 732 1.04 0.69-1.55 .868
ICH from brain VM APOE e2 152 0.47 0.10-2.35 .361
ANGPTL4 rs11672433 (AA or AG) 151 1.89 0.78-4.59 .158
EPHB4 rs314308 (AA or AG) 153 1.85 0.69-4.96 .222
IL1B-31T>C, rs1143627 CC) 152 1.22 0.37-4.04 .750
IL6-174G>C rs1800795 (GG) 151 0.46 0.15-1.44 .185
ITGB8 rs10486391 (AA) 152 0.82 0.35-1.96 .664
TNF-238G>A rs361525 (AA or AG) 151 0.93 0.24-3.54 .915
ADAM17 rs10495565 151 0.71 0.41-1.21 .208
ADAM17 rs12474540 153 0.70 0.42-1.17 .171
PTPN14 rs2936018 153 0.89 0.41-1.93 .770
USH2A rs700024 147 2.77 1.13-6.80 .026
Liver VM APOE e2 702 0.95 0.53-1.73 .876
ANGPTL4 rs11672433 (AA or AG) 697 1.26 0.81-1.96 .300
EPHB4 rs314308 (AA or AG) 708 1.19 0.79-1.79 .404
IL1B-31T>C, rs1143627 (CC) 712 0.40 0.19-0.86 .019
IL6-174G>C rs1800795 (GG) 704 1.03 0.68-1.56 .884
ITGB8 rs10486391 (AA) 714 0.77 0.52-1.15 .202
TNF-238G>A rs361525 (AA or AG) 711 0.78 0.41-1.48 .445
ADAM17 rs10495565 715 1.31 0.98-1.77 .071
ADAM17 rs12474540 714 1.42 1.08-1.87 .013
PTPN14 rs2936018 706 1.17 0.82-1.67 .375
USH2A rs700024 698 1.20 0.77-1.85 .418
(Continues)
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overall BVMC cohort. In analysis stratified by HHT gene,
among ENG mutation carriers only, there was a significant
association of one of the four variants, ADAM17
rs12474540, and a trend toward association of two other
TGFB modifier SNPs with liver (but not lung) VM. There
was a trend in the same direction in the overall cohort. The
lung AVM associations originally reported were also stron-
ger among ENG mutation carriers (Kawasaki et al., 2014).
There was also a trend toward association of another of
these variants, USH2A rs700024, with ICH from brain
VM. These findings may indicate that the TGFB modifier
loci variants are associated with multiple HHT phenotypes,
but a larger cohort will be required to confirm this. It is
not clear why we do not detect a lung AVM association in
our cohort, and do not replicate the original finding (Kawa-
saki et al., 2014). To check for a possible effect of differ-
ent lung AVM ascertainment on the genetic association
results, we defined a severe lung AVM phenotype closer to
the lung AVM phenotype definition used in the cohort
studied in the original report (Letteboer et al., 2015; Paw-
likowska et al., 2015), but did not detect statistically signif-
icant associations with any of the 4 TGFB modifier
variants. The disparity in genetic association results may
also be influenced by methodological differences: the pub-
lished analysis of lung AVM was performed in families,
testing for transmission of risk alleles; we performed a
case–control association analysis in a large cohort of
mostly unrelated subjects. Another difference between our
cohorts was that the BVMC targeted enrollment of 25%
brain VM positive patients, resulting in cohort with 21%
brain VM positive patients. This proportion is within the
upper end of the range of prevalence of brain VM positive
patients reported by other cohorts (5%–23% (Akers et al.,
2013)), so we do not expect it to significantly influence the
results of our association analysis, however it does repre-
sent a divergence from completely unbiased enrollment.
Finally, our cohort was North American Caucasians, the
original findings were in Dutch and French Caucasians
(Benzinou et al., 2012; Kawasaki et al., 2014). It is possi-
ble for population stratification even among/within Cau-
casian cohorts to influence genetic association results.
We did not detect significant associations between any of
the 7 variants previously reported in sporadic BAVM or ICH
with HHT brain VM or ICH. Possible explanations include
different genetic influences on sporadic and HHT brain
AVM, that the original findings (from small cohorts and
unreplicated) were false positives, and a false negative, due
to lack of power to detect small effects in our cohort. In the
case of ACVRL1 c.314-35A>G, the sporadic brain AVM-
associated variant that we found to also be associated with
VM in HHT (Pawlikowska et al., 2015), the original finding
had been replicated in multiple sporadic brain AVM cohorts,
and the variant was in an HHT gene. The BVMC cohort of
752 subjects is substantial for a rare disease such as HHT,
but may not be sufficient to detect associations of small
effect size. We did observe several associations with the
same direction of effect as in previous studies; a larger cohort
is required to validate these associations. The BVMC is
recruiting a second cohort of 800 HHT patients.
Our findings suggest the effects of genetic modifier
variants are complex, but given the functional data from
animal and in vitro models for the involvement of
ADAM17 and PTPN14 in HHT biology (Benzinou et al.,
2012; Kawasaki et al., 2014), it is of interest to revisit
these in larger cohorts. Identification and validation of
genetic modifiers could inform prognosis and guide clinical
management of HHT patients and provide potentially use-
ful stratifier biomarkers for clinical trials.
TABLE 2 (Continued)
Phenotype Polymorphism (risk genotypes) n OR 95% CI p
Lung AVM APOE e2 715 0.91 0.58-1.43 .691
ANGPTL4 rs11672433 (AA or AG) 710 0.88 0.62-1.25 .471
EPHB4 rs314308 (AA or AG) 721 0.78 0.57-1.07 .120
IL1B-31T>C, rs1143627 CC) 724 0.98 0.61-1.57 .938
IL6-174G>C rs1800795 (GG) 716 1.10 0.80-1.51 .555
ITGB8 rs10486391 (AA) 727 0.70 0.52-0.96 .027
TNF-238G>A rs361525 (AA or AG) 724 0.54 0.33-0.89 .015
ADAM17 rs10495565 728 0.98 0.79-1.22 .879
ADAM17 rs12474540 726 0.92 0.75-1.14 .462
PTPN14 rs2936018 719 1.00 0.77-1.31 .994
USH2A rs700024 710 1.03 0.72-1.46 .892
p, multivariable regression adjusted for gender, age at last follow-up and family clustering.
AVM, arteriovenous malformation; ICH, intracerebral hemorrhage; VM, vascular malformation.
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